US 11,976,297 B2
Engineered immune cells with receptor cross-talk
Alexander Kamb, Agoura Hills, CA (US)
Assigned to A2 BIOTHERAPEUTICS, INC., Agoura Hills, CA (US)
Filed by A2 BIOTHERAPEUTICS, INC., Agoura Hills, CA (US)
Filed on Sep. 21, 2021, as Appl. No. 17/480,466.
Claims priority of provisional application 63/081,250, filed on Sep. 21, 2020.
Claims priority of provisional application 63/081,237, filed on Sep. 21, 2020.
Claims priority of provisional application 63/081,256, filed on Sep. 21, 2020.
Claims priority of provisional application 63/081,231, filed on Sep. 21, 2020.
Claims priority of provisional application 63/081,242, filed on Sep. 21, 2020.
Claims priority of provisional application 63/081,229, filed on Sep. 21, 2020.
Claims priority of provisional application 63/081,248, filed on Sep. 21, 2020.
Claims priority of provisional application 63/081,258, filed on Sep. 21, 2020.
Prior Publication US 2022/0090014 A1, Mar. 24, 2022
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C12N 15/85 (2006.01)
CPC C12N 5/0637 (2013.01) [A61K 35/17 (2013.01); C07K 14/4702 (2013.01); C07K 14/7051 (2013.01); C12N 15/85 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/715 (2013.01); C12N 2510/00 (2013.01)] 20 Claims
 
1. An engineered immune cell comprising:
an activating receptor that triggers a cytotoxic signal that promotes a cytotoxic response of the engineered immune cell when the activating receptor binds a first ligand of a target cell; and
a blocking receptor that sends an interfering signal that inhibits the cytotoxic response of the engineered immune cell when the blocking receptor binds a second ligand of the target cell, each receptor comprising an extracellular binding domain, a hinge, a transmembrane domain, and an intracellular domain and said blocking receptor comprising a hinge that comprises a peptide of at least 24 contiguous amino acids of SEQ ID NO: 84, said peptide derived from a leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1), wherein cross-talk between the activating receptor and the blocking receptor affects an activation threshold for the cytotoxic response.